245 related articles for article (PubMed ID: 32321634)
1. Urgent avenues in the treatment of COVID-19: Targeting downstream inflammation to prevent catastrophic syndrome.
Quartuccio L; Semerano L; Benucci M; Boissier MC; De Vita S
Joint Bone Spine; 2020 May; 87(3):191-193. PubMed ID: 32321634
[No Abstract] [Full Text] [Related]
2. COVID-19: consider cytokine storm syndromes and immunosuppression.
Mehta P; McAuley DF; Brown M; Sanchez E; Tattersall RS; Manson JJ;
Lancet; 2020 Mar; 395(10229):1033-1034. PubMed ID: 32192578
[No Abstract] [Full Text] [Related]
3. Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment.
Yeleswaram S; Smith P; Burn T; Covington M; Juvekar A; Li Y; Squier P; Langmuir P
Clin Immunol; 2020 Sep; 218():108517. PubMed ID: 32585295
[TBL] [Abstract][Full Text] [Related]
4. Inflammatory cytokines, T lymphocyte subsets, and ritonavir involved in liver injury of COVID-19 patients.
Liao S; Zhan K; Gan L; Bai Y; Li J; Yuan G; Cai Y; Zhang A; He S; Mei Z
Signal Transduct Target Ther; 2020 Oct; 5(1):255. PubMed ID: 33130825
[No Abstract] [Full Text] [Related]
5. Targeting inflammation and cytokine storm in COVID-19.
Huang Q; Wu X; Zheng X; Luo S; Xu S; Weng J
Pharmacol Res; 2020 Sep; 159():105051. PubMed ID: 32603772
[No Abstract] [Full Text] [Related]
6. A plea for the pathogenic role of immune complexes in severe Covid-19.
Vuitton DA; Vuitton L; Seillès E; Galanaud P
Clin Immunol; 2020 Aug; 217():108493. PubMed ID: 32526273
[No Abstract] [Full Text] [Related]
7. Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19.
Laurence J; Mulvey JJ; Seshadri M; Racanelli A; Harp J; Schenck EJ; Zappetti D; Horn EM; Magro CM
Clin Immunol; 2020 Oct; 219():108555. PubMed ID: 32771488
[TBL] [Abstract][Full Text] [Related]
8. Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia.
Lin L; Lu L; Cao W; Li T
Emerg Microbes Infect; 2020 Dec; 9(1):727-732. PubMed ID: 32196410
[TBL] [Abstract][Full Text] [Related]
9. Old and new antirheumatic drugs for the treatment of COVID-19.
Benucci M; Damiani A; Infantino M; Manfredi M; Quartuccio L
Joint Bone Spine; 2020 May; 87(3):195-197. PubMed ID: 32321635
[No Abstract] [Full Text] [Related]
10. Terminal complement inhibition dampens the inflammation during COVID-19.
Kulasekararaj AG; Lazana I; Large J; Posadas K; Eagleton H; Lord Villajin J; Zuckerman M; Gandhi S; Marsh JCW
Br J Haematol; 2020 Aug; 190(3):e141-e143. PubMed ID: 32495372
[No Abstract] [Full Text] [Related]
11. More questions than answers, and a way ahead.
La Manna G
G Ital Nefrol; 2020 Apr; 37(2):. PubMed ID: 32281753
[No Abstract] [Full Text] [Related]
12. COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome?
Sarzi-Puttini P; Giorgi V; Sirotti S; Marotto D; Ardizzone S; Rizzardini G; Antinori S; Galli M
Clin Exp Rheumatol; 2020; 38(2):337-342. PubMed ID: 32202240
[TBL] [Abstract][Full Text] [Related]
13. [Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Should we target the virus, the cell or the disease?].
Nisole S; Saulnier A; Gatignol A
Virologie (Montrouge); 2020 Jun; 24(3):135-141. PubMed ID: 32648548
[No Abstract] [Full Text] [Related]
14. An updated insight into the molecular pathogenesis, secondary complications and potential therapeutics of COVID-19 pandemic.
Jamwal S; Gautam A; Elsworth J; Kumar M; Chawla R; Kumar P
Life Sci; 2020 Sep; 257():118105. PubMed ID: 32687917
[TBL] [Abstract][Full Text] [Related]
15. Lymphopenia during the COVID-19 infection: What it shows and what can be learned.
Tavakolpour S; Rakhshandehroo T; Wei EX; Rashidian M
Immunol Lett; 2020 Sep; 225():31-32. PubMed ID: 32569607
[No Abstract] [Full Text] [Related]
16. Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy.
Mastellos DC; Pires da Silva BGP; Fonseca BAL; Fonseca NP; Auxiliadora-Martins M; Mastaglio S; Ruggeri A; Sironi M; Radermacher P; Chrysanthopoulou A; Skendros P; Ritis K; Manfra I; Iacobelli S; Huber-Lang M; Nilsson B; Yancopoulou D; Connolly ES; Garlanda C; Ciceri F; Risitano AM; Calado RT; Lambris JD
Clin Immunol; 2020 Nov; 220():108598. PubMed ID: 32961333
[TBL] [Abstract][Full Text] [Related]
17. Novel therapeutic targets for SARS-CoV-2-induced acute lung injury: Targeting a potential IL-1β/neutrophil extracellular traps feedback loop.
Yaqinuddin A; Kashir J
Med Hypotheses; 2020 Oct; 143():109906. PubMed ID: 32505910
[TBL] [Abstract][Full Text] [Related]
18. Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19.
Zhang X; Zhang Y; Qiao W; Zhang J; Qi Z
Int Immunopharmacol; 2020 Sep; 86():106749. PubMed ID: 32645632
[TBL] [Abstract][Full Text] [Related]
19. Weak Induction of Interferon Expression by Severe Acute Respiratory Syndrome Coronavirus 2 Supports Clinical Trials of Interferon-λ to Treat Early Coronavirus Disease 2019.
O'Brien TR; Thomas DL; Jackson SS; Prokunina-Olsson L; Donnelly RP; Hartmann R
Clin Infect Dis; 2020 Sep; 71(6):1410-1412. PubMed ID: 32301957
[No Abstract] [Full Text] [Related]
20. Immune-Mediated Coagulopathy in COVID-19 Infection.
Vadasz Z; Brenner B; Toubi E
Semin Thromb Hemost; 2020 Oct; 46(7):838-840. PubMed ID: 32877959
[No Abstract] [Full Text] [Related]
[Next] [New Search]
